Business Wire

Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis

Share

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of moderately-to-severely active rheumatoid arthritis (RA) are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier this year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005875/en/

“We are encouraged by the durability of both the efficacy and safety profiles of filgotinib seen in these studies,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. “These data suggest that filgotinib if approved, may play an important role in helping people living with rheumatoid arthritis achieve sustained, clinically meaningful responses.”

“These recent updates from the FINCH 1 and 3 trials continue to provide consistent evidence to support filgotinib’s profile in RA patients. In the second half of the FINCH 1 and FINCH 3 trials, filgotinib exhibited the same favorable safety profile seen in the first 24 weeks, including similar rates of thrombotic events as previously observed, as well as persistent efficacy,” said Dr. Walid Abi-Saab, Chief Medical Officer, Galapagos.

Detailed Week 52 results from the FINCH 1 and 3 trials will be submitted for presentation at a future medical conference.

A Marketing Authorization Application (MAA) for filgotinib for the treatment of adults with rheumatoid arthritis is now under evaluation by the European Medicines Agency (EMA) and a New Drug Application (NDA) for filgotinib has been submitted to the Japanese Ministry of Health, Labor and Welfare (MHLW). Gilead plans to file a New Drug Application (NDA) for filgotinib for the treatment of rheumatoid arthritis in the United States including the FINCH 1 and FINCH 3 Week 52 data later this year.

Filgotinib is an investigational agent and is not approved anywhere. Its efficacy and safety have not been established by any regulatory authorities.

About the FINCH 1 and FINCH 3 Programs

The FINCH Phase 3 program investigated the efficacy and safety of 100 mg and 200 mg filgotinib once daily, in RA patient populations ranging from early stage to biologic-experienced patients. FINCH 1 was a 52‑week, randomized, placebo- and adalimumab-controlled trial in combination with methotrexate (MTX) enrolling 1,759 adult patients with moderately to severely active RA who had inadequate response to MTX. The primary endpoint was ACR20 at week 12. The trial included radiographic assessment at weeks 24 and 52. FINCH 3 was a 52‑week, randomized trial in 1,252 MTX-naïve patients to evaluate filgotinib 200mg alone and filgotinib 100 mg or 200 mg combined with methotrexate versus methotrexate alone in methotrexate-naïve patients. The primary endpoint was ACR20 at week 24. Radiographic progression was also assessed.

More information about clinical trials with filgotinib can be accessed at: www.clinicaltrials.gov.

About the Filgotinib Collaboration

Galapagos and Gilead entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications. The FINCH Phase 3 studies are among several clinical trials of filgotinib in inflammatory diseases, including the EQUATOR Phase 2 program in psoriatic arthritis, the TORTUGA Phase 2 study in ankylosing spondylitis, the DIVERSITY Phase 3 trial in Crohn’s disease (also small bowel and fistulizing Crohn’s disease Phase 2 studies) and the Phase 3 SELECTION trial in ulcerative colitis.

About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

Galapagos Forward-Looking Statements

This release may contain forward-looking statements with respect to Galapagos, including statements regarding Galapagos’ strategic ambitions, the mechanism of action and potential safety and efficacy of filgotinib, the anticipated timing of clinical studies with filgotinib and the progression and results of such studies. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos’ results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of filgotinib due to safety, efficacy or other reasons), Galapagos’ reliance on collaborations with third parties (including its collaboration partner for filgotinib, Gilead), and estimating the commercial potential of Galapagos’ product candidates. A further list and description of these risks, uncertainties and other risks can be found in Galapagos’ Securities and Exchange Commission (SEC) filings and reports, including in Galapagos’ most recent annual report on form 20-F filed with the SEC and subsequent filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

Gilead Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility that the final efficacy, safety and tolerability results from these studies differ materially from those reported in this press release, the possibility of unfavorable results from other clinical trials involving filgotinib, and the risk that the EMA, FDA and other regulatory agencies may not approve filgotinib for the treatment of RA in the currently anticipated timelines or at all, and any marketing approvals, if granted, may have significant limitations on its use. Further, it is possible that the parties may make a strategic decision to discontinue development of filgotinib, and as a result, filgotinib may never be successfully commercialized. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Contact information

Gilead
Sung Lee, Investors
(650) 524-7792

Arran Attridge, Media
(650) 425-8975

Galapagos
Elizabeth Goodwin, Investors
(781) 460-1784

Sofie Van Gijsel, Investors
+32 485 19 14 15

Carmen Vroonen, Media
+32 473 824 874

Evelyn Fox, Media
+31 6 53 591 999

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AG&P gjør en strategisk investering i Kanfer Shipping21.11.2019 07:22:00 CETPress release

Det ledende og globale selskapet for logistikk av flytende naturgass (LNG) Atlantic Gulf & Pacific (AG&P), har gjort en strategisk investering i Kanfer Shipping (Kanfer). Kanfer er en innovativ utvikler av sjøtransport, maritime break-bulk-løsninger, flytende lagringsfasiliteter samt bunkring av LNG, med base i Norge. Sammen vil Kanfer og AG&P gjøre LNG mer tilgjengelig og kommersielt levedyktig for kunder i nye og voksende naturgassmarkeder. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20191120006068/no/ AG&P makes a strategic investment in Norway-based Kanfer Shipping to make LNG more accessible and commercially viable for downstream customers. Kanfer has captured the attention of the global LNG maritime infrastructure industry with its revolutionary Detachable Stern Vessel (left), that makes it easier, faster, and more efficient to break-bulk and transport LNG. (Photo: Business Wire) Kanfer har allerede gjort seg be

Inotrem Announces Enrollment of First Patient in its Phase IIb ASTONISH Trial for Nangibotide in the Treatment of Septic Shock21.11.2019 07:00:00 CETPress release

Inotrem S.A., a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, through its knowledge of the TREM-1 pathway biology, announced today it has initiated its Phase IIb ASTONISH trial to evaluate nangibotide in the treatment of septic shock and has enrolled the first patient in the trial. Nangibotide is a TREM-1 inhibitor peptide with the potential to restore appropriate inflammatory response, vascular function, and improve post septic shock survival. Septic shock is the ultimate complication of sepsis. The incidence of septic shock continuously raises and mortality remains elevated (35%) in developed countries. There is currently no specific therapy approved for this indication besides antibiotics and supportive treatment. Inotrem’s therapeutic solution has the potential to become the first mechanism-based treatment for septic shock. Nangibotide in septic shock has been granted the fast track status in September 2019 by the FDA and the PRIME status in

Study Uses Masimo Patient SafetyNet™ and rainbow Acoustic Monitoring® to Investigate the Incidence of Desaturation and Bradypnea in Postoperative Patients21.11.2019 07:00:00 CETPress release

Masimo (NASDAQ: MASI) announced today that in a study recently published in the Journal of Clinical Monitoring and Computing, researchers at Nippon Medical School in Tokyo, Japan used Masimo Patient SafetyNet™ and rainbow Acoustic Monitoring® (RAM®), acoustic respiration rate monitoring with RRa®, as a centralized continuous monitoring system to identify the incidence and predictors of desaturation and bradypnea in postoperative patients – concluding that “Use of monitoring systems might provide a safety net for postoperative patients.”1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191120006062/en/ Masimo Patient SafetyNet™, Root® with Radius-7®, RRa®, and SET® (Photo: Business Wire) Patient SafetyNet is a supplemental remote monitoring, patient surveillance, and clinician notification system that works in conjunction with Masimo and third-party bedside monitoring devices to display near real-time data at central stations.

NTT Com Wins Two MEF 3.0 Proof of Concept Awards21.11.2019 06:03:00 CETPress release

NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO: 9432), announced today it received MEF 3.0 Proof of Concept Awards in two categories, “MEF3.0 SD-WAN Implementation 2019” and “Network Slicing Implementation 2019,” during the MEF 3.0 Proof of Concept Showcase event held in the U.S. city of Los Angeles from November 18 to 22. The showcase was organized by the Metro Ethernet Forum (MEF), a global telecom industry alliance with more than 220 members. NTT Com attended the showcase to introduce an SD-WAN1 service and a 5G-related proof of concept (PoC)2, joining other telecom carriers and manufacturers that presented their own initiatives for judging. About MEF Awards https://www.mef.net/2019_MEF_Awards MEF3.0 SD-WAN Implementation 2019 NTT Com’s orchestrated virtualized multivendor SD-WAN services received the award presented for the best SD-WAN service in compliance with MEF specifications. The NTT Com servic

Innodisk and Microsoft Announce Strategic Alliance, Pushing for New Out-of-Band Standard for Secure AIoT Device Management21.11.2019 01:41:00 CETPress release

Innodisk is hosting media and industry partners at an exclusive Taipei event with a focus on establishing a new standard of AIoT storage and device management. Joining Innodisk’s president Randy Chien is Microsoft’s APAC GM of IoT Device Experience, Shirley Strachan, who together will announce the two companies’ strategic partnership. The event will also be attended by some of the main actors in the industry, SuperMicro, DFI, Avalue, and IEI, who will be showcasing how their products can integrate Innodisk and Microsoft’s new solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191120006043/en/ Innodisk is announcing the strategic partnership with Microsoft and push out of band management to AIoT edge devices. (Photo: Business Wire) World’s First SSD with Integrated Azure Sphere With the new InnoAGE™ SSD with Microsoft’s MCU, Azure Sphere, Innodisk introduces an innovative flash device with independent Out-of-Band connec

CORRECTING and REPLACING Salesforce Selects Esri as Key Geospatial Partner20.11.2019 18:29:00 CETPress release

The first sentence of the fifth paragraph should read: Salesforce Maps will be released at Dreamforce 2019 (instead of: Salesforce Maps will be released at Dreamforce 2019 and available for purchase in February). The corrected release reads: SALESFORCE SELECTS ESRI AS KEY GEOSPATIAL PARTNER Today at Dreamforce, Esri, the global leader in mapping and location intelligence, announced that Salesforce has selected Esri as the key geospatial partner for Salesforce Maps. Salesforce is integrating Esri’s ArcGIS Living Atlas, the foremost collection of global geographic data and basemaps. Salesforce Maps users will be able to access Esri’s ArcGIS Online, the leading geospatial cloud, giving businesses the ability to analyze and visualize massive amounts of geographic and demographic data. “Geo-services are becoming mainstream. Now Salesforce customers will unlock new insights and patterns in their customer data, enabling them to ‘See What Others Can’t’ through geographic visualization, using m